Readers are directed to the PDF version of this article.
Publisher’s note: This guidance has been reviewed in 2020 and is considered to be out of date. Up-to-date guidance, including an algorithm for testing, can be found in this consensus statement.
Jane Diggle reflects on the growing role of incretin-based therapies across cardio–renal–metabolic care, and highlights resources to support their use.
12 May 2026